Total and anatomically contextualized quantitative 18F-DCFPyL PET at biochemical recurrence to predict subsequent biochemical progression-free survival in patients with prostate cancer. This is an ...
Positron emission tomography (PET) has emerged as a pivotal imaging modality in the detection, staging and management of prostate cancer. By administering a radiotracer that selectively binds to ...
Exploration of the utility of alkaline phosphatase level (ALP) as a prognostic factor in patients with metastatic castrate resistant prostate cancer (mCRPC) receiving prechemotherapy abiraterone ...
Positron Emission Tomography-Computed Tomography using Prostate-Specific Membrane Antigen (PSMA PET/CT) is notable for its superior sensitivity and specificity in detecting recurrent PCa and is under ...
A multicenter study led by London Health Sciences Centre Research Institute (LHSCRI), Lawson Research Institute of St. Joseph's Health Care London (Lawson), and University Health Network (UHN) has ...
FDA approved Pylarify TruVu, a higher-radioactivity-concentration formulation of piflufolastat F 18 designed to increase batch size and distribution efficiency while maintaining the established ...
Verywell Health on MSN
Stage 4 prostate cancer treatments and prognosis
Medically reviewed by Jamin Brahmbhatt, MD Key Takeaways Stage 4 prostate cancer is advanced and has spread beyond the prostate.Hormone therapy is often used to treat stage 4 prostate cancer by ...
Flow Space on MSN
Prostate cancer progression: What caregivers need to know
Fear can take over the moment prostate cancer progresses. These questions can help caregivers replace confusion with clarity, ...
Dr. Glenn Bauman, Scientist at LHSCRI and Radiation Oncologist at London Health Sciences Centre (LHSC), stands in front of the positron emission tomography (PET) scanner. LONDON, ON – A multicentre ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results